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Abstract
Background: Fentanyl-detected illicit drug overdose deaths in British Columbia (BC) recently increased dramatically
from 13 deaths in 2012 to 90 deaths in 2014, signaling an emerging public health concern. Illicit fentanyl is sold as
pills or powders, often mixed with other substances like heroin or oxycodone; reports from coroners suggested that
fentanyl was frequently taken unknowingly by people who use drugs. This study aimed to assess the prevalence
and characteristics of fentanyl use among clients accessing harm reduction (HR) services in BC.
Methods: Participants attending HR services at 17 sites across BC were invited to complete an anonymous
questionnaire describing drugs they have used within the last 3 days and provide a urine sample to test for
fentanyl. Data from eligible participants were analyzed using descriptive, bivariate, and multivariate statistical
methods.
Results: Surveys from 17 HR sites were received, resulting in analysis of responses from 242 eligible participants. Most
participants used multiple substances (median = 3), with crystal meth (59 %) and heroin (52 %) use most frequently
reported. Seventy participants (29 %) tested positive for fentanyl, 73 % of whom did not report using fentanyl.
Controlling for age, gender, and health authority, reported use of fentanyl (odds ratio (OR) = 6.13, 95 % confidence
interval (CI) = [2.52, 15.78], p < 0.001) and crystal methamphetamine (OR = 3.82, 95 % CI = [1.79, 8.63], p < 0.001) use
were significantly associated with fentanyl detection.
Conclusions: The proportion of those testing positive who did not report knowingly using fentanyl represents a
considerable public health concern. The risk of overdose among this vulnerable population highlights the need for
targeted HR strategies, such as increased accessibility to naloxone, overdose education, and urine screens.
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Background
Use of illicit fentanyl has emerged as a dangerous trend
among people who use drugs in British Columbia (BC).
Fentanyl-detected, illicit drug overdose deaths in BC have
increased dramatically between 2012 and 2015 [1].
Reports from the BC Coroners Service suggest many of
those testing positive for fentanyl were unknowingly using
the substance [1]. The rapid increase in fentanyl-detected
overdoses and risk of unintentional administration
presents an emerging public health concern in BC.
Fentanyl is a synthetic opioid, far more potent than
morphine and heroin, clinically used in anesthesia, and for
management of chronic pain, pharmaceutical fentanyl is
only available as transdermal patches in Canada [2].
Recently in Canada, illicit fentanyl has been sold as
pills or powders, often mixed with other substances
like heroin or oxycodone and, on many occasions,
ingested unintentionally by people who use drugs due
to undisclosured pill/powder contents [2]. Historically,
nonpharmaceutical fentanyl and its analogs have been
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sold under various street names, while recent prepara-
tions, called “green jellies” or “street oxy,” have become
available across Canada [2, 3].
Fentanyl overdose can lead to respiratory depression,
followed by decreased mental status, brain damage, and
death. The potency of fentanyl considerably increases the
risk of overdose. This is particularly concerning with illicit
fentanyl, as doses can be highly variable and people using
may be opioid naïve. The pharmacodynamic properties of
fentanyl metabolites may also lead to prolonged physiologic
effects in the context of an overdose, similar to longer act-
ing opioids [4]. This complicates the emergency response
and may increase the risk of complications, as patients can
re-narcotize following reversal with naloxone [5].
Several clusters of fentanyl-related overdose deaths have
been reported in both Canada and the USA. Between
2002 and 2004, 112 fentanyl-detected deaths were
reported in Ontario [6]. These deaths were associated with
a variety of fentanyl formulations and co-administered
substances; however, a particular pattern of illicit use was
not reported. A large cluster of 1013 fentanyl-related
deaths between 2005 and 2007 in six US states was found
to be associated with illicit fentanyl mixed with heroin and
cocaine [7]. Another fentanyl-associated cluster of illicit
drug deaths was identified in 2013 in Rhode Island [8].
Between 2009 and 2014 in Canada, fentanyl was deemed
a cause or contributory cause in at least 655 deaths and
was detected in at least 1019 drug poisoning deaths [9]. In
BC, fentanyl-detected overdose deaths increased sevenfold
from 13 deaths in 2012 to 90 in 2014 [9]. This represented
a considerable increase in the proportion of total fentanyl-
detected illicit drug overdose deaths, from 5 % in 2012 to
over 25 % in 2014.
In response to the emerging threat of fentanyl use and
subsequent overdose to people who use drugs in BC, this
study was developed to assess the prevalence and charac-
teristics of fentanyl use among clients accessing harm
reduction (HR) services in BC. Increased understanding of
these patterns may lead to more effectively targeted harm
reduction strategies, such as health promotion campaigns
targeting unsafe drug use practices and take-home nalox-
one programs.
Methods
The study used a cross-sectional design linking surveys
of demographics and substance usage patterns with
fentanyl urine tests. The Behavioural Ethics Review
Boards at the University of BC and Interior Health
Authority granted ethics approval.
Study materials
The survey used questions adapted from an annual survey
of clients at HR sites conducted by the BC Centre for
Disease Control [10]. Study materials were reviewed with
a group of five peers (people with experience using drugs)
at the Vancouver Area Network of Drug Users (VANDU).
Materials were also distributed to potential sites in order
to check for suitability and acceptability of study design,
as there was potential for urine testing to be perceived as
a threatening activity.
Although renal clearance of fentanyl varies by age
and dosage, the urine levels of norfentanyl, a fentanyl
metabolite, typically become negligible within 3 days
of administration [11]. The surveys collected informa-
tion on substance use within 3 days prior to survey
completion and urine collection, as this was deemed
the optimal window to link urine norfentanyl detec-
tion with fentanyl use.
After consultation with medical facilities already testing
patients’ urine for fentanyl, BNTX Rapid Response TM
fentanyl urine strip tests at a detection level of 20 ng/ml
norfentanyl were chosen as the method for measuring
urine norfentanyl levels [12].
Recruitment and survey distribution
In BC, supplies for safer sex and drug use (e.g., needles
and condoms) are distributed by a network of over 200
HR sites, including public health units and community
service organizations [10]. We estimated a total sample
size of 385 respondents would allow us to report results
at 95 % confidence level of +/− 5 % for an unknown
population. Based on general population density, 4–10
sites in each of five regional health authorities were invited
directly by the British Columbia Centre for Disease Control
(BCCDC) or the regional HR coordinator to participate in
the study. Questionnaires, participant refusal tracking sheet,
urine test strips and instructions, and honorarium funds
were mailed to each participating site. Site staff were
responsible for recruiting clients, getting informed consent
from participants, administering the questionnaire, testing
the urine sample, and providing the $5 participant honorar-
ium. Unique client ID labels were used to maintain
anonymity and link the survey, urine sample, and urine
strip result. Data were collected from February through
March 2015.
The sample population included individuals who
reported using substances within the preceding 3 days,
were over 19 years of age, presented to a participating site
during the study period, and were able to give verbal,
informed consent.
Data cleaning and analysis
Data was entered into a Microsoft Access database and
imported into the R statistical software environment for
cleaning and analysis. This was performed using R pack-
age (version 3.1.1) & R Studio (version 0.98.1062) with
functions from the MASS package (version 7.3-40).
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Participants less than 19 years of age, who reported no
substance use within the previous 3 days or whose
fentanyl urine screen results were unlinked with the
associated surveys, were excluded from analysis.
Substance use data was cleaned and recoded for analysis.
For the substance use questions, blanks were assumed to
indicate negative responses.
Descriptive statistical techniques were applied to
demographic and substance use variables. To maintain
anonymity due to small cell sizes, location data was
aggregated to the health authority level.
Odds ratios were calculated using logistic regression
for number and type of substances used, health author-
ity, gender, age group, and history of overdose. Analysis
of variance (ANOVA) with the chi-square test was run
on age and health authority variables to determine their
significance. Significant variables were then controlled
for age, gender, and health authority in a multivariate
regression model.
Results
Overall, 294 surveys were received from 17 HR supply
distribution sites (Fig. 1). Only 28 individuals approached
to participate in the study declined, corresponding to a
participation rate of 91.3 %. Fifty-two participants were
excluded from analysis resulting in a final sample size of
242:41 due to the absence of accurate linkage between
urine test results and surveys, two were less than 19 years
of age, five did not list their age, and four reported no
substance use in the previous 3 days.
Descriptive analysis
Demographic and substance use information is
summarized in Table 1. A higher proportion of males
(58 %) participated in the study than females (40 %),
and 40–49-year-olds had the highest representation
(34 %), followed by 30–39-years-olds (28 %). Sample
sizes varied among the province’s five health author-
ities; Island Health was under-sampled and comprised
only 6 % (n = 14) of total participants.
As per Fig. 2, crystal methamphetamine was the most
frequently reported substance used (58 %), followed by
heroin (52 %). A total of 31 (13 %) individuals reported
using fentanyl. Reported substance use varied signifi-
cantly between health authorities (Fig. 3). The majority
of participants reported using more than one substance
(88 %) in the previous 3 days (median = 3). A total of 24
individuals (10 %) reported a history of overdose within
the previous month and 5 (2 %) within the previous
week. Approximately 29 % (n = 70) of the participants
tested positive for fentanyl, 73 % (n = 51) of which
reported no known fentanyl use within the previous
3 days. All participants reporting an overdose within the
previous week (n = 5) tested positive for fentanyl, two of
which did not report knowingly using the substance.
Bivariate analysis
Odds ratios are summarized in Table 1. Among substance
use patterns, those substances most significantly correlated
with positive fentanyl urine screens were crystal metham-
phetamine (odds ratio (OR) = 3.50, 95 % confidence interval
(CI) = [1.88, 6.86], p < 0.001) and fentanyl (OR = 4.97, 95 %
CI = [2.28, 11.20], p < 0.001). Health authority was signifi-
cantly correlated with a positive fentanyl urine screen (p <
0.01); in particular, Island Health was highly correlated
(OR = 3.60, 95 % CI = [1.10, 13.08]). All other variables,
including gender, age, history of overdose, and number of
substances used, were found not to be significantly corre-
lated with fentanyl detection.
Multivariate analysis
A multivariate logistic regression model was created to
control for associations between variables (Table 2). After
controlling for age, gender, location, and health authority,
fentanyl (OR = 6.13, 95 % CI = [2.52, 15.78], p <0.001) and
crystal methamphetamine (OR = 3.82, 95 % CI = [1.79,
8.63], p <0.001) use remained significantly associated with
fentanyl detection.
Discussion
The patterns of substance use reported by participants
differed from those identified by a recent provincial survey
[13]. The higher reported use of crystal meth in our
sample corresponds to anecdotal reports of a trend among
experienced users in BC toward crystal methamphetamine
and away from heroin and crack [14]. Differences in
reported pattern of use between this study and the annual
provincial survey may be due to smaller sample size
(17 vs. 30+ sites) and time of year (winter vs. sum-
mer). BC’s natural geographic features and winter
Fig. 1 Outline of exclusion criteria for data analysis
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weather conditions may facilitate or restrict access to
certain substances in various urban, rural, and remote
communities. The significant correlation between
location and fentanyl detection may be related to these
factors.
The results of our study support the hypothesis that a
considerable portion of fentanyl use in BC is uninten-
tional, with 73 % of those testing positive for fentanyl,
reporting no known fentanyl use within the previous
3 days. This represents a substantial risk to people who
use drugs, as the dose of fentanyl in substances consumed
may vary and individuals may be opioid naïve, creating an
optimal scenario for overdose.
Reported use of heroin or other opioids besides
fentanyl was not significantly correlated with fentanyl
positivity, while crystal methamphetamine was signifi-
cantly associated. The intentional inclusion of fentanyl
in crystal methamphetamine by distributors is counter-
intuitive, as opioids tend to oppose many of the
intended effects of stimulants, and this group of users
Table 1 Descriptive and bivariate analysis of demographics, substance use patterns, and associated fentanyl-detection as reported
by participants
Variable Total number (%) Number positive (%) OR [95 %CI] p value
Substance use
Methadone 73 (30 %) 18 (25 %) 0.74 [0.39, 1.36] 0.34
Morphine 97 (40 %) 27 (28 %) 0.91 [0.51, 1.61] 0.76
Dilaudid 55 (23 %) 13 (24 %) 0.71 [0.34, 1.39] 0.33
Oxycodone 23 (10 %) 9 (39 %) 1.67 [0.66, 4.00] 0.26
Fentanyl 31 (13 %) 19 (61 %) 4.97 [2.28, 11.20] <0.001
Benzodiazapines 48 (20 %) 14 (29 %) 1.01 [0.49, 2.00] 0.97
Stimulants NOSa 25 (10 %) 7 (28 %) 0.95 [0.35, 2.30] 0.91
Heroin 126 (52 %) 42 (33 %) 1.57 [0.90, 2.78] 0.12
Cocaine powder 65 (27 %) 16 (25 %) 0.74 [0.38, 1.40] 0.37
Crack 78 (32 %) 21 (27 %) 0.86 [0.47, 1.56] 0.64
Crystal meth 143 (59 %) 55 (38 %) 3.50 [1.88, 6.86] <0.001
Marijuana 55 (23 %) 14 (25 %) 0.80 [0.39, 1.55] 0.52
Number of substances used
1 substanceb 30 (12 %) 5 (17 %) 1.0 0.12
>1 substance 212 (88 %) 65 (31 %) 2.21 [0.87, 6.78] 0.12
Overdose
Overdose within last month 24 (10 %) 7 (29 %) 0.98 [0.36, 2.39] 0.97
Overdose within last week 5 (2 %) 5 (100 %) – –
Health authority
Fraser Health Authority 57 (24 %) 22 (39 %) 1.26 [0.59, 2.69] <0.001
Interior Health Authority 54 (22 %) 9 (17 %) 0.40 [0.16, 0.96] <0.001
Northern Health Authority 57 (24 %) 10 (18 %) 0.43 [0.17, 1.00] <0.001
Vancouver Coastal Healthb 60 (25 %) 20 (33 %) - = 1.0 <0.001
Island Health 14 (6 %) 9 (64 %) 3.60 [1.10, 13.08] <0.001
Age group
19–29 45 (19 %) 12 (27 %) 0.99 [0.41, 2.31] 0.85
30–39b 67 (28 %) 18 (27 %) 1.0 0.85
40–49 83 (34 %) 27 (33 %) 1.31 [0.65, 2.70] 0.85
50+ 47 (19 %) 13 (28 %) 1.04 [0.44, 2.40] 0.85
Gender
Female 98 (40 %) 32 (33 %) 1.31 [0.75, 2.31] 0.34
Maleb 141 (58 %) 38 (27 %) 1.0 0.34
aNot otherwise specified
bVariable used as reference for OR calculations
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may be opioid naïve and more likely to overdose.
Although this finding was unexpected, there have been
reports of individuals using opioid/stimulant combina-
tions, such as “speedballs” combining heroin and cocaine,
as well as individuals experiencing opioid overdose symp-
toms following crystal methamphetamine use [15]. These
combinations rely on the variability in pharmacodynamics
between the opioid and stimulant, causing the transition
between depressant and stimulant effects. Another pos-
sible explanation for the association may be unintentional
contamination through handling and storage prior to
distribution.
Intentional fentanyl use was highly correlated with
fentanyl detection in the urine; however, 12 out of 31
participants reporting fentanyl use tested negative. It is
possible that, due to the rapid clearance of fentanyl by
the kidneys, fentanyl metabolites may be below the
detectable level when a small amount and/or full 3 days
between consumption and testing [12, 16]. Alternately,
individuals reporting fentanyl use may actually be taking
something entirely different.
The risk of overdose from unknown presence of fentanyl
in street drugs highlights the need for strategies that focus
on overdose prevention, recognition, and response. BC
public health agencies have developed messaging
campaigns to increase awareness of fentanyl-related
overdoses and recommend precautionary strategies
based on the unintentional fentanyl use identified by
this study [17]. Providing overdose response training and
naloxone, an opioid overdose antidote, is needed to reduce
the harms of fentanyl overdose. Take-home naloxone
programs implemented in BC and across North America
support early reversal for opioid overdoses, as subsequent
respiratory depression may lead to brain damage and death
[18, 19]. While these programs traditionally target people
who use opioids, the unintentional use of fentanyl may
support a need to broaden coverage to people who use
other substances, as well as their friends and family.








































Fig. 2 Prevalence of specific substance use and proportion of positive fentanyl test results among participants using these substances







































Fig. 3 Percent of participants reporting specific substance use by health authority
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Given that illicit fentanyl may be mixed into many
street drugs, the availability of street drug checking for
fentanyl could reduce the risk of accidental overdose.
However, in the absence of a cheap rapid fentanyl detec-
tion test that could be used on a drug sample, fentanyl
urine testing strips could be provided to people who use
drugs as an additional harm reduction service.
The elevated prevalence of fentanyl use also has implica-
tions on the use of naloxone by paramedics or in the
emergency room (ER) to treat suspected opioid overdoses,
and for the management of withdrawal for patients in
detoxification centers. Given the pharmacodynamic prop-
erties of fentanyl, overdoses may result in more prolonged
respiratory depression than other opioids and may require
higher levels of naloxone for reversal [5]. Clinicians should
consider fentanyl urine testing when managing overdoses
in ER. Although this may not change the clinical manage-
ment of the overdose, test results can serve as an oppor-
tunity to educate patients about their overdose and
increase uptake of take-home naloxone programs.
In the time between the data collection phase and the
publication of this study, fentanyl has become a public
health concern in many jurisdictions outside BC, including
other areas in Canada and the USA [9, 20, 21]. The recom-
mendations stemming from our findings could reduce
harms due to overdose in all regions affected by the
presence of illicit fentanyl in the street market.
Several characteristics of this study limit the scope of
our conclusions. Those sampled from participating HR
sites are a small subset of individuals accessing harm
reduction sites and of all people who use drugs in BC.
The exclusion of 48 participants, in part due to the
submission of unlinked surveys and test results from
one site, also reduced the power of the study. Another
site only sent samples and surveys of participants who
tested positive for fentanyl, which may lead to an over
estimate of fentanyl prevalence.
Technical limitations include cross-reactivity of the
fentanyl urine tests and fentanyl analogs, such as sufenta-
nyl. The rapid clearance of fentanyl may also result in
negative test results, even if it was used within the 3-day
window. The study was also limited by the exclusion of
those younger than 19 years of age due to ethics approval;
however, only a few of fentanyl-detected illicit drug deaths
in BC have occurred in people under 19 years. Other limi-
tations include reliance on self-reported questionnaires,
the assumption that nonresponses represented negative
answers and other biases inherent in cross-sectional study
designs.
Conclusions
The results of this study demonstrate that illicit fentanyl
is a considerable risk to people who use drugs in BC,
particularly among those who consume it unknowingly.
The widespread use of crystal methamphetamine and its
association with fentanyl detection suggests that even
those using stimulants may be at risk of opioid overdose,
thus emphasizing the importance of broadening overdose
education and prevention programs.
Further research is required to verify the associations
made in this report and may include investigation into drug
distribution patterns, as well as a review of coroners’ files to
identify substances implicated in illicit drug-associated
deaths.
While the increase in fentanyl availability and fentanyl-
detected deaths is alarming, support of harm reduction
strategies can help mitigate the risks. Public health agencies
have taken steps to combat this trend; however, further
engagement is necessary to reduce the impact of illicit
fentanyl on this vulnerable population.
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Table 2 Multivariate, additive logistic regression models of
significant variables controlled for age, gender, location, and
concurrent opioid use
Variable OR [95 % CI] p value
Fentanyl 6.13 [2.52, 15.78] <0.001
Crystal meth 3.82 [1.79, 8.63] <0.001
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